Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial

  1. Das, R.
  2. Blázquez-Gamero, D.
  3. Bernstein, D.I.
  4. Gantt, S.
  5. Bautista, O.
  6. Beck, K.
  7. Conlon, A.
  8. Rosenbloom, D.I.S.
  9. Wang, D.
  10. Ritter, M.
  11. Arnold, B.
  12. Annunziato, P.
  13. Russell, K.L.
Journal:
The Lancet Infectious Diseases

ISSN: 1474-4457 1473-3099

Year of publication: 2023

Volume: 23

Issue: 12

Pages: 1383-1394

Type: Article

DOI: 10.1016/S1473-3099(23)00343-2 GOOGLE SCHOLAR

Sustainable development goals